Modern plasma fractionation

被引:216
作者
Burnouf, Thierry [1 ]
机构
[1] Human Plasma Prod Serv, F-59800 Lille, France
关键词
D O I
10.1016/j.tmrv.2006.11.001
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Protein products fractionated from human plasma are an essential class of therapeutics used, often as the only available option, in the prevention, management, and treatment of life-threatening conditions resulting from trauma, congenital deficiencies, immunologic disorders, or infections. Modern plasma product production technology remains largely based on the ethanol fractionation process, but much has evolved in the last few years to improve product purity, to enhance the recovery of immunoglobulin G, and to isolate new plasma proteins, such as alpha 1-protease inhibitor, von Willebrand factor, and protein C. Because of the human origin of the starting material and the pooling of 10000 to 50000 donations required for industrial processing, the major risk associated to plasma products is the transmission of blood-borne infectious agents. A complete set of measures-and, most particularly, the use of dedicated viral inactivation and removal treatments-has been implemented throughout the production chain of fractionated plasma products over the last 20 years to ensure optimal safety, in particular, and not exclusively, against HIV, hepatitis B virus, and hepatitis C virus. In this review, we summarize the practices of the modern plasma fractionation industry from the collection of the raw plasma material to the industrial manufacture of fractionated products. We describe the quality requirements of plasma for fractionation and the various treatments applied for the inactivation and removal of blood-borne infectious agents and provide examples of methods used for the purification of the various classes of plasma protein therapies. We also highlight aspects of the good manufacturing practices and the regulatory environment that govern the whole chain of production. In a regulated and professional environment, fractionated plasma products manufactured by modern processes are certainly among the lowest-risk therapeutic biological products in use today. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:101 / 117
页数:17
相关论文
共 59 条
[1]
Clearance of prions during plasma protein manufacture [J].
Burdick, MD ;
Pifat, DY ;
Petteway, SR ;
Cai, K .
TRANSFUSION MEDICINE REVIEWS, 2006, 20 (01) :57-62
[2]
BURGSTALER E, 2003, CURRENT INSTRUMENTAT, P95
[3]
BIOCHEMICAL AND BIOLOGICAL PROPERTIES OF AN ALPHA-1-ANTITRYPSIN CONCENTRATE [J].
BURNOUF, T ;
CONSTANS, J ;
CLERC, A ;
DESCAMPS, J ;
MARTINACHE, L ;
GOUDEMAND, M .
VOX SANGUINIS, 1987, 52 (04) :291-297
[4]
A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system [J].
Burnouf, T. ;
Goubran, H. A. ;
Radosevich, M. ;
Sayed, M. A. ;
Gorgy, G. ;
El-Ekiaby, M. .
VOX SANGUINIS, 2006, 91 (01) :56-62
[5]
Place of nanofiltration for assuring viral safety of biologicals [J].
Burnouf, T ;
Radosevich, M ;
Goubran, HA ;
Willkommen, H .
CURRENT NANOSCIENCE, 2005, 1 (03) :189-201
[6]
Assessment of complement activation during membrane-based plasmapheresis procedures [J].
Burnouf, T ;
Eber, M ;
Kientz, D ;
Cazenave, JP ;
Burkhardt, T .
JOURNAL OF CLINICAL APHERESIS, 2004, 19 (03) :142-147
[7]
CHROMATOGRAPHY IN PLASMA FRACTIONATION - BENEFITS AND FUTURE-TRENDS [J].
BURNOUF, T .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 664 (01) :3-15
[8]
PROPERTIES OF A HIGHLY PURIFIED HUMAN-PLASMA FACTOR-IX-C THERAPEUTIC CONCENTRATE PREPARED BY CONVENTIONAL CHROMATOGRAPHY [J].
BURNOUF, T ;
MICHALSKI, C ;
GOUDEMAND, M ;
HUART, JJ .
VOX SANGUINIS, 1989, 57 (04) :225-232
[9]
Residual cell content in plasma produced by three centrifugal apheresis procedures [J].
Burnouf, T ;
Kappelsberger, C ;
Frank, K ;
Burkhardt, T .
TRANSFUSION, 2003, 43 (11) :1522-1526
[10]
Nanofiltration of plasma-derived biopharmaceutical products [J].
Burnouf, T ;
Radosevich, M .
HAEMOPHILIA, 2003, 9 (01) :24-37